What is Evelo Biosciences's earnings per share (EPS)?

Evelo Biosciences (EVLO) reported diluted earnings per share of $-1.31 for fiscal year 2022. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Evelo Biosciences Financials

EVLO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2023 Currency USD FYE December

This page shows Evelo Biosciences (EVLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Evelo Biosciences passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Evelo Biosciences generates $0.88 in operating cash flow (-$101.2M OCF vs -$114.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$106.4M

YoY+6.0%

Evelo Biosciences's EBITDA was -$106.4M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.0% from the prior year.

Net Income

-$114.5M

YoY+6.3%

Evelo Biosciences reported -$114.5M in net income in fiscal year 2022. This represents an increase of 6.3% from the prior year.

EPS (Diluted)

$-1.31

Evelo Biosciences earned $-1.31 per diluted share (EPS) in fiscal year 2022. This represents an increase of 43.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$101.9M

YoY-3.7%

Evelo Biosciences generated -$101.9M in free cash flow in fiscal year 2022, representing cash available after capex. This represents a decrease of 3.7% from the prior year.

Cash & Debt

$47.9M

YoY-30.0%

5Y CAGR+4.6%

Evelo Biosciences held $47.9M in cash against $43.6M in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

Evelo Biosciences had 6M shares outstanding in fiscal year 2022. This represents a decrease of 89.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$78.6M

YoY-6.1%

5Y CAGR+31.5%

Evelo Biosciences invested $78.6M in research and development in fiscal year 2022. This represents a decrease of 6.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$622K

YoY-59.1%

5Y CAGR-18.6%

Evelo Biosciences invested $622K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 59.1% from the prior year.

EVLO Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$78.6M-6.1%	$83.6M+20.1%	$69.6M+10.3%	$63.1M+58.3%	$39.9M+99.9%	$20.0M
SG&A Expenses	$29.9M-5.8%	$31.8M+42.6%	$22.3M-4.1%	$23.2M+27.5%	$18.2M+140.5%	$7.6M
Operating Income	-$108.5M+6.0%	-$115.4M-25.6%	-$91.9M-6.4%	-$86.4M-48.6%	-$58.1M-111.0%	-$27.5M
Interest Expense	N/A	N/A	N/A	N/A	$900K+80.0%	$500K
Income Tax	$930K+117.3%	$428K+4.6%	$409K+115.3%	$190K	$0	$0
Net Income	-$114.5M+6.3%	-$122.2M-30.4%	-$93.7M-9.6%	-$85.5M-50.1%	-$56.9M-103.0%	-$28.0M
EPS (Diluted)	$-1.31	$-2.31+2.5%	$-2.37	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.5M-50.2%	$13.0M-27.0%	$17.9M	N/A	$21.9M+3.3%	$21.2M+9.8%	$19.3M	N/A
SG&A Expenses	$3.9M-20.8%	$4.9M-30.2%	$7.0M	N/A	$7.1M-14.8%	$8.4M-11.2%	$9.4M	N/A
Operating Income	-$11.2M+42.9%	-$19.6M+21.4%	-$24.9M	N/A	-$29.1M+1.8%	-$29.6M-3.0%	-$28.7M	N/A
Interest Expense	$1.3M	N/A	N/A	N/A	$1.1M	N/A	N/A	N/A
Income Tax	-$17K-107.3%	$233K+60.7%	$145K	N/A	$107K-34.4%	$163K+40.5%	$116K	N/A
Net Income	-$12.4M+41.4%	-$21.1M+16.7%	-$25.3M	N/A	-$30.6M0.0%	-$30.6M-2.3%	-$29.9M	N/A
EPS (Diluted)	$-0.71+81.2%	$-3.78	$-0.23	N/A	$-5.66+29.9%	$-8.07-1341.1%	$-0.56	N/A

EVLO Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$64.4M-26.7%	$87.9M-3.1%	$90.6M-0.3%	$90.9M-43.1%	$159.9M+265.1%	$43.8M
Current Assets	$51.6M-27.4%	$71.0M+0.1%	$71.0M-12.4%	$81.0M-46.6%	$151.6M+291.0%	$38.8M
Cash & Equivalents	$47.9M-30.0%	$68.4M-0.6%	$68.9M-11.5%	$77.8M-16.4%	$93.1M+143.4%	$38.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$69.4M-12.3%	$79.2M+31.7%	$60.2M+95.8%	$30.7M+34.1%	$22.9M-76.7%	$98.5M
Current Liabilities	$12.4M-28.6%	$17.4M-12.5%	$19.8M+103.6%	$9.7M+5.5%	$9.2M+140.6%	$3.8M
Long-Term Debt	$43.6M-6.3%	$46.6M+54.9%	$30.0M+53.0%	$19.6M+59.6%	$12.3M+23.5%	$10.0M
Total Equity	-$5.0M-157.6%	$8.7M-71.6%	$30.5M-49.4%	$60.2M-56.0%	$136.9M+350.3%	-$54.7M
Retained Earnings	-$529.2M-27.6%	-$414.7M-41.8%	-$292.5M-47.1%	-$198.9M-75.4%	-$113.4M-101.0%	-$56.4M

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Total Assets	$20.6M-0.9%	$20.8M-50.4%	$42.0M-34.9%	$64.4M-25.4%	$86.3M-22.8%	$111.9M+90.2%	$58.8M-33.1%	$87.9M
Current Assets	$18.9M+68.1%	$11.3M-62.6%	$30.1M-41.7%	$51.6M-28.7%	$72.3M-25.4%	$97.0M+125.0%	$43.1M-39.3%	$71.0M
Cash & Equivalents	$17.3M+126.5%	$7.6M-72.3%	$27.5M-42.7%	$47.9M-30.6%	$69.1M-24.9%	$92.0M+132.2%	$39.6M-42.1%	$68.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$47.3M-29.3%	$66.9M-3.5%	$69.4M-0.1%	$69.4M-9.8%	$77.0M+1.0%	$76.3M+0.8%	$75.6M-4.5%	$79.2M
Current Liabilities	$39.8M-28.4%	$55.5M-3.0%	$57.2M+361.9%	$12.4M-54.0%	$26.9M+25.5%	$21.4M+32.6%	$16.2M-6.9%	$17.4M
Long-Term Debt	$0	$0	$0-100.0%	$43.6M+19.0%	$36.6M-10.1%	$40.7M-9.0%	$44.8M-3.8%	$46.6M
Total Equity	-$26.7M+42.1%	-$46.1M-68.4%	-$27.4M-448.6%	-$5.0M-153.5%	$9.3M-73.8%	$35.6M+312.2%	-$16.8M-293.9%	$8.7M
Retained Earnings	-$588.0M-2.1%	-$575.7M-3.8%	-$554.6M-4.8%	-$529.2M-4.7%	-$505.7M-6.4%	-$475.1M-6.9%	-$444.6M-7.2%	-$414.7M

EVLO Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$101.2M-4.7%	-$96.7M-32.4%	-$73.1M-1.5%	-$72.0M-52.2%	-$47.3M-103.2%	-$23.3M
Capital Expenditures	$622K-59.1%	$1.5M+15.0%	$1.3M-56.4%	$3.0M-44.5%	$5.5M+213.5%	$1.7M
Free Cash Flow	-$101.9M-3.7%	-$98.2M-32.1%	-$74.4M+0.8%	-$75.0M-42.2%	-$52.7M-110.9%	-$25.0M
Investing Cash Flow	-$622K+58.0%	-$1.5M-12.6%	-$1.3M-102.5%	$52.0M+186.4%	-$60.1M-3351.7%	-$1.7M
Financing Cash Flow	$81.7M-16.3%	$97.5M+49.0%	$65.5M+1211.4%	$5.0M-96.9%	$162.0M+230.9%	$49.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Operating Cash Flow	-$10.4M+47.5%	-$19.8M+2.2%	-$20.3M+12.6%	-$23.2M-2.7%	-$22.6M+14.8%	-$26.5M+8.3%	-$28.9M-3.9%	-$27.8M
Capital Expenditures	$47K	$0-100.0%	$12K-94.7%	$228K+2433.3%	$9K-96.1%	$232K+51.6%	$153K+134.5%	-$443K
Free Cash Flow	-$10.5M+47.3%	-$19.8M+2.3%	-$20.3M+13.4%	-$23.4M-3.6%	-$22.6M+15.6%	-$26.8M+8.0%	-$29.1M-2.8%	-$28.3M
Investing Cash Flow	$513K	$0+100.0%	-$12K+94.7%	-$228K-2433.3%	-$9K+96.1%	-$232K-51.6%	-$153K-132.2%	$475K
Financing Cash Flow	$19.2M	$0+100.0%	-$199K-111.4%	$1.7M+161.5%	$665K-99.2%	$79.1M+67535.9%	$117K+192.9%	-$126K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EVLO Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-1409.7%-1102.4pp	-307.3%-165.3pp	-142.0%-100.4pp	-41.6%	N/A
Return on Assets	-177.7%-38.7pp	-139.0%-35.7pp	-103.3%-9.3pp	-94.0%-58.4pp	-35.6%+28.4pp	-64.0%
Current Ratio	4.16+0.1	4.09+0.5	3.58-4.7	8.31-8.1	16.42+6.3	10.10
Debt-to-Equity	-8.74-14.1	5.37+4.4	0.99+0.7	0.33+0.2	0.09+0.3	-0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-327.5%-241.7pp	-85.7%	N/A	N/A
Return on Assets	-59.9%+41.4pp	-101.4%-41.0pp	-60.4%	N/A	-35.4%-8.1pp	-27.3%+23.5pp	-50.8%	N/A
Current Ratio	0.48+0.3	0.20-0.3	0.53-3.6	4.16+1.5	2.69-1.8	4.52+1.9	2.67-1.4	4.09
Debt-to-Equity	0.000.0	0.000.0	0.00+8.7	-8.74-12.7	3.93+2.8	1.14+3.8	-2.66-8.0	5.37
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$5.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Scopus Biopharma Inc. SCPS

$13K

Renovacare RCAR

$9K

Virpax Pharmaceuticals Inc VRPX

$5.7M

Statera Biopharma Inc STAB

$7K

Q Biomed QBIO

$15K

Frequently Asked Questions

Is Evelo Biosciences profitable?

No, Evelo Biosciences (EVLO) reported a net income of -$114.5M in fiscal year 2022.

What is Evelo Biosciences's EBITDA?

Evelo Biosciences (EVLO) had EBITDA of -$106.4M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Evelo Biosciences have?

As of fiscal year 2022, Evelo Biosciences (EVLO) had $47.9M in cash and equivalents against $43.6M in long-term debt.

What is Evelo Biosciences's free cash flow?

Evelo Biosciences (EVLO) generated -$101.9M in free cash flow during fiscal year 2022. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Evelo Biosciences's operating cash flow?

Evelo Biosciences (EVLO) generated -$101.2M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Evelo Biosciences's total assets?

Evelo Biosciences (EVLO) had $64.4M in total assets as of fiscal year 2022, including both current and long-term assets.

What are Evelo Biosciences's capital expenditures?

Evelo Biosciences (EVLO) invested $622K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does Evelo Biosciences spend on research and development?

Evelo Biosciences (EVLO) invested $78.6M in research and development during fiscal year 2022.

How many shares does Evelo Biosciences have outstanding?

Evelo Biosciences (EVLO) had 6M shares outstanding as of fiscal year 2022.

What is Evelo Biosciences's current ratio?

Evelo Biosciences (EVLO) had a current ratio of 4.16 as of fiscal year 2022, which is generally considered healthy.

What is Evelo Biosciences's debt-to-equity ratio?

Evelo Biosciences (EVLO) had a debt-to-equity ratio of -8.74 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Evelo Biosciences's return on assets (ROA)?

Evelo Biosciences (EVLO) had a return on assets of -177.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is Evelo Biosciences's cash runway?

Based on fiscal year 2022 data, Evelo Biosciences (EVLO) had $47.9M in cash against an annual operating cash burn of $101.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Evelo Biosciences's debt-to-equity ratio negative or unusual?

Evelo Biosciences (EVLO) has negative shareholder equity of -$5.0M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Evelo Biosciences's Piotroski F-Score?

Evelo Biosciences (EVLO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Evelo Biosciences's earnings high quality?

Evelo Biosciences (EVLO) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.